Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge in cancer medicine. The aggressive tumor biology and remarkable resistance to conventional anti-tumor treatments are reflected in a 5-year PDAC survival rate of less than 8%. Despite significant scientific and clinical efforts the dismal prognosis of PDAC has remained unchanged for almost 30 years, and PDAC has been predicted to become the second leading cause of cancer related death within this decade.

Our Clinical Research Unit 5002 (CRU 5002) focuses on defined molecular subgroups of PDAC and explores subtype-specific genome dynamics and their implications on PDAC progression and therapy resistance. We believe that our findings can provide unique and novel avenues to refine PDAC treatment strategies towards stratification-based precision medicine, thus improving the outcome of PDAC patients.

About the CRU 5002

Projects and contact information

Our Concept

The CRU 5002 aims at improving our understanding of subtype specificity in PDAC biology and therapy resistance and at creating solid foundations for stratification-based tailored treatment strategies in PDAC.

Scientific and Central Projects

Our projects aim at defining the mechanisms, functional relevance and therapeutic potential of altered genome dynamics in selected PDAC subtypes.

Our Team

All of the CRU 5002's staff at a glance. If you require any further information regarding the CRU 5002, please do not hesitate to contact us. 

News and upcoming events

KFO5002

CRU 5002 1st scientific retreat

SAVE THE DATE: CRU 5002's first scientific retreat

Contact information

Contact persons at a glance

Speaker

Prof. Dr. med. Volker Ellenrieder

contact information

secretariat

  • Head of the Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology

    Head of the Comprehensive Cancer Center Göttingen

Coordinator

PD Dr. med. Elisabeth Heßmann

contact information

Scientific Assistant

Alexander Müller

contact information

Follow us